A Phase 3 interventional study of Rivaroxaban and Acetylsalicylic Acid in Thrombosis, sponsored by Janssen Research & Development, LLC. Completed at 42 sites in 10 countries. Open to participants aged 2 Years to 8 Years. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing rivaroxaban in Thrombosis — 4 open to participants now, 4 under way, 1 of them phase 3. Rivaroxaban · Thrombosis.
Among the 30 studies testing rivaroxaban in Thrombosis, this one is the 13th largest by enrollment, is one of 3 that started in 2016, is one of 11 in phase 3, and was the 17th registered.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
Browse Thrombosis studies →4 of the 30 studies testing rivaroxaban in Thrombosis are open now, in 4 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Queen Mary University of London · Sites in United Kingdom
Ages 16+
Nova Scotia Health Authority · Sites in Canada
Ages 55+
Lebanese University · Sites in Lebanon
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 2 Years to 8 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 4 · Phase 3 11 · Phase 4 5
First in 2004; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 112 is above the median of 83 across 530 interventional studies indexed under Thrombosis.
Median enrollment 84 across the 30 interventional studies. Of the 22 that completed or were terminated, 11 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Johnson & Johnson has 5 studies filed under Thrombosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing rivaroxaban in Thrombosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613840Massachusetts General HospitalPersonalizing Thromboprophylaxis for Patients With Peripheral Artery Disease | 2027-04-29 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing rivaroxaban in Thrombosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Purpose of this study is to characterize the single and multiple-dose pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/ PD) profiles after oral rivaroxaban therapy administered to pediatric participants 2 to 8 years of age with single ventricle physiology who have completed the Fontan procedure within 4 months prior to enrollment (Part A) and to evaluate the safety and efficacy of rivaroxaban, administered twice daily (exposure matched to rivaroxaban 10 milligram [mg] once daily in adults) compared to acetylsalicylic acid (ASA), given once daily (approximately 5 milligram per kilogram [mg/kg]) for thromboprophylaxis in pediatric participants 2 to 8 years of age with single ventricle physiology who have completed the Fontan procedure within 4 months prior to enrollment.
Part A: This part includes a 12-day Initial PK, PD, and Safety Assessment Period. Participants in Part A will not participate in Part B. Randomization in Part B of this study will begin once the cumulative data from the Initial PK, PD, and Safety Assessment Period in Part A are deemed acceptable by the Independent Data Monitoring Committee. Part A of the study will consist of an up to 21-day Screening Period, a 12-day Initial PK, PD, and Safety Assessment Period, a 12-month Open-Label Treatment Period, and a 30-day Follow-Up phone contact. Part B: Participants will be randomly assigned to two treatment groups and randomization ratio will be 2:1 for rivaroxaban and ASA. ASA will be used as control. There will be an up to a 21-day Screening Period, a 12 month Open-Label Treatment Period and a 30-day Follow-Up phone contact.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Rivaroxaban
Drug: Acetylsalicylic Acid
Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to \<8 kilogram (kg) will receive 2.2 milligram (mg); 8 to \<10 kg will receive 3.2 mg; 10 to\<12 kg will receive 3.4 mg; 12 to \<20 will receive 4.0 mg and 20 to \<30 will receive 5.0 mg.
Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
Percentage of Participants With Any Thrombotic Event (Venous or Arterial and Symptomatic or Asymptomatic)
Thrombotic event was defined as the appearance of a new thrombotic burden within the cardiovascular system on either routine surveillance or clinically indicated imaging, or the occurrence of a clinical event known to be strongly associated with thrombus (such as cardioembolic stroke, pulmonary embolism). The event included ischemic stroke, pulmonary embolism, venous thrombosis, arterial/intracardiac thrombosis, and other thrombosis.
Time frame: Up to 12 months
Plasma Concentration of Rivaroxaban at Day 1 (0.5-1.5 Hours Postdose)
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 1: 0.5-1.5 hours postdose
Plasma Concentration of Rivaroxaban at Day 1 (1.5-4 Hours Postdose)
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 1: 1.5-4 hours postdose
Plasma Concentration of Rivaroxaban at Day 4 (Up to 3 Hours Predose)
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 4: Up to 3 hours predose
Plasma Concentration of Rivaroxaban at Day 4 (0.5-1.5 Hours Postdose)
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 4: 0.5-1.5 hours postdose
Plasma Concentration of Rivaroxaban at Day 4 (1.5-4 Hours Postdose)
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 4: 1.5-4 hours postdose
Plasma Concentration of Rivaroxaban at Day 4 (6-8 Hours Postdose)
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 4: 6-8 hours postdose
Plasma Concentration of Rivaroxaban at Month 3 (Up to 3 Hours Predose)
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Month 3: Up to 3 hours predose
Plasma Concentration of Rivaroxaban at Month 3 (0.5-1.5 Hours Postdose)
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Month 3: 0.5-1.5 hours postdose
Plasma Concentration of Rivaroxaban at Month 3 (2.5-4 Hours Postdose)
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Month 3: 2.5-4 hours postdose
Percentage of Participants With Bleeding Events
Bleeding events were categorized into major, clinically relevant non-major bleeding (CRNM), and trivial bleeding events. Major bleeding: overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more; or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults; or occurring in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; or contributing to death. CRNM bleeding: overt bleeding not meeting the criteria for major bleeding but associated with: Medical intervention, or Unscheduled contact with a physician, cessation of study treatment, or Discomfort for the subject such as pain, or Impairment of activities of daily life. Trivial bleeding: any other overt bleeding event that does not meet criteria for CRNM bleeding.
Time frame: Up to 12 months
Absolute Prothrombin Time (PT) at Day 1 (0.5-1.5 Hours Postdose)
Absolute prothrombin time was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 1: 0.5-1.5 hours postdose
Absolute PT at Day 1 (1.5-4 Hours Postdose)
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 1: 1.5-4 hours postdose
Absolute PT at Day 4 (Up to 3 Hours Predose)
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here.
Time frame: Day 4: Up to 3 hours predose
Absolute PT at Day 4 (0.5-1.5 Hours Postdose)
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 4: 0.5-1.5 hours postdose
Absolute PT at Day 4 (1.5-4 Hours Postdose)
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 4: 1.5-4 hours postdose
Absolute PT at Day 4 (6-8 Hours Postdose)
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 4: 6-8 hours postdose
Absolute PT at Month 3 (Up to 3 Hours Predose)
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Month 3: Up to 3 hours predose
Absolute PT at Month 3 (0.5-1.5 Hours Postdose)
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Month 3: 0.5-1.5 hours postdose
Absolute PT at Month 3 (2.5-4 Hours Postdose)
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Month 3: 2.5-4 hours postdose
Activated Partial Thromboplastin Time (aPTT) at Day 1 (0.5-1.5 Hours Postdose)
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 1: 0.5-1.5 hours postdose
aPTT at Day 1 (1.5-4 Hours Postdose)
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and average of the participants included in the given time-range is presented here.
Time frame: Day 1: 1.5-4 hours postdose
aPTT at Day 4 (Up to 3 Hours Predose)
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 4: Up to 3 hours predose
aPTT at Day 4 (0.5-1.5 Hours Postdose)
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here.
Time frame: Day 4: 0.5-1.5 hours postdose
aPTT at Day 4 (1.5-4 Hours Postdose)
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average for the participants included in the given time-range is presented here.
Time frame: Day 4: 1.5-4 hours postdose
aPTT at Day 4 (6-8 Hours Postdose)
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 4: 6-8 hours postdose
aPTT at Month 3 (Up to 3 Hours Predose)
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Month 3: Up to 3 hours predose
aPTT at Month 3 (0.5-1.5 Hours Postdose)
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Month 3: 0.5-1.5 hours postdose
aPTT at Month 3 (2.5-4 Hours Postdose)
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Month 3: 2.5-4 hours postdose
Anti-FXa at Day 1 (0.5-1.5 Hours Postdose)
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 1: 0.5-1.5 hours postdose
Anti-FXa at Day 1 (1.5-4 Hours Postdose)
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 1: 1.5-4 hours postdose
Anti-FXa at Day 4 (6-8 Hours Postdose)
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Day 4: 6-8 hours postdose
Anti-FXa at Month 3 (Up to 3 Hours Predose)
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Month 3: Up to 3 hours predose
Anti-FXa at Month 3 (0.5-1.5 Hours Postdose)
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Month 3: 0.5-1.5 hours postdose
Anti-FXa at Month 3 (2.5-4 Hours Postdose)
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
Time frame: Month 3: 2.5-4 hours postdose
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs were defined as those adverse events (AEs) that occurred from the first day of study drug to the last day of study drug + 2 days inclusive. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Time frame: Up to 12 months
| Milestone | Rivaroxaban (Part A) | Rivaroxaban (Part B) | Aspirin (Part B) |
|---|---|---|---|
| Started | 12 | 66 | 34 |
| Completed | 11 | 63 | 33 |
| Not completed | 1 | 3 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 |
Thrombotic event was defined as the appearance of a new thrombotic burden within the cardiovascular system on either routine surveillance or clinically indicated imaging, or the occurrence of a clinical event known to be strongly associated with thrombus (such as cardioembolic stroke, pulmonary embolism). The event included ischemic stroke, pulmonary embolism, venous thrombosis, arterial/intracardiac thrombosis, and other thrombosis.
| percentage of participants | Rivaroxaban (Part A) | Rivaroxaban (Part B) | Aspirin (Part B) |
|---|---|---|---|
| Any thrombotic event | 8.3 | 1.6 | 8.8 |
| Ischemic stroke | 0 | 0 | 2.9 |
| Pulmonary embolism | 0 | 1.6 | 0 |
| Venous thrombosis | 8.3 | 0 | 5.9 |
| Arterial/intracardiac thrombosis | 0 | 0 | 0 |
| Other thrombosis | 0 | 0 | 0 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| micrograms per liter (mcg/L) | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Plasma Concentration of Rivaroxaban at Day 1 (0.5-1.5 Hours Postdose) | 46.69 ± 39.4 | 92.86 ± 72.6 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Plasma Concentration of Rivaroxaban at Day 1 (1.5-4 Hours Postdose) | 86.62 ± 43.1 | 103.61 ± 62.6 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Plasma Concentration of Rivaroxaban at Day 4 (Up to 3 Hours Predose) | 36.58 ± 37.4 | — |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Plasma Concentration of Rivaroxaban at Day 4 (0.5-1.5 Hours Postdose) | 107.58 ± 54.2 | — |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Plasma Concentration of Rivaroxaban at Day 4 (1.5-4 Hours Postdose) | 147.18 ± 116 | — |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Plasma Concentration of Rivaroxaban at Day 4 (6-8 Hours Postdose) | 66.81 ± 64.6 | — |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Plasma Concentration of Rivaroxaban at Month 3 (Up to 3 Hours Predose) | 38.23 ± 25.7 | 29.41 ± 25.5 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Plasma Concentration of Rivaroxaban at Month 3 (0.5-1.5 Hours Postdose) | 86.25 ± 32.0 | 94.12 ± 82.2 |
Plasma rivaroxaban concentrations for Parts A and B were assessed. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Plasma Concentration of Rivaroxaban at Month 3 (2.5-4 Hours Postdose) | 96.67 ± 58.4 | 102.99 ± 56.0 |
Bleeding events were categorized into major, clinically relevant non-major bleeding (CRNM), and trivial bleeding events. Major bleeding: overt bleeding and associated with a fall in hemoglobin of 2 gram per deciliter (g/dL) or more; or leading to a transfusion of the equivalent of 2 or more units of packed red blood cells or whole blood in adults; or occurring in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal; or contributing to death. CRNM bleeding: overt bleeding not meeting the criteria for major bleeding but associated with: Medical intervention, or Unscheduled contact with a physician, cessation of study treatment, or Discomfort for the subject such as pain, or Impairment of activities of daily life. Trivial bleeding: any other overt bleeding event that does not meet criteria for CRNM bleeding.
| percentage of participants | Rivaroxaban (Part A) | Rivaroxaban (Part B) | Aspirin (Part B) |
|---|---|---|---|
| Any bleeding event | 33.3 | 35.9 | 41.2 |
| Major Bleeding | 0 | 1.6 | 0 |
| Clinically relevant non-major bleeding | 8.3 | 6.3 | 8.8 |
| Trivial bleeding | 25.0 | 32.8 | 35.3 |
Absolute prothrombin time was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Absolute Prothrombin Time (PT) at Day 1 (0.5-1.5 Hours Postdose) | 15.46 ± 1.90 | 18.02 ± 2.58 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Absolute PT at Day 1 (1.5-4 Hours Postdose) | 16.58 ± 1.84 | 18.76 ± 2.25 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Absolute PT at Day 4 (Up to 3 Hours Predose) | 15.21 ± 1.54 | — |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Absolute PT at Day 4 (0.5-1.5 Hours Postdose) | 17.95 ± 2.10 | — |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Absolute PT at Day 4 (1.5-4 Hours Postdose) | 18.73 ± 3.30 | — |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Absolute PT at Day 4 (6-8 Hours Postdose) | 16.13 ± 2.13 | — |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Absolute PT at Month 3 (Up to 3 Hours Predose) | 17.59 ± 2.65 | 16.45 ± 2.27 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Absolute PT at Month 3 (0.5-1.5 Hours Postdose) | 20.13 ± 3.55 | 18.89 ± 3.69 |
Absolute PT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Absolute PT at Month 3 (2.5-4 Hours Postdose) | 19.14 ± 2.61 | 19.69 ± 2.81 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Activated Partial Thromboplastin Time (aPTT) at Day 1 (0.5-1.5 Hours Postdose) | 31.4 ± 4.68 | 30.69 ± 8.23 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| aPTT at Day 1 (1.5-4 Hours Postdose) | 32.83 ± 3.79 | 30.25 ± 3.80 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| aPTT at Day 4 (Up to 3 Hours Predose) | 33.08 ± 5.68 | — |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| aPTT at Day 4 (0.5-1.5 Hours Postdose) | 36.17 ± 6.99 | — |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average for the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| aPTT at Day 4 (1.5-4 Hours Postdose) | 37.58 ± 8.45 | — |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| aPTT at Day 4 (6-8 Hours Postdose) | 32.83 ± 5.94 | — |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| aPTT at Month 3 (Up to 3 Hours Predose) | 25.36 ± 3.76 | 28.70 ± 3.76 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| aPTT at Month 3 (0.5-1.5 Hours Postdose) | 26.60 ± 2.55 | 31.15 ± 4.17 |
aPTT was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| seconds | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| aPTT at Month 3 (2.5-4 Hours Postdose) | 26.74 ± 1.79 | 31.67 ± 3.58 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Anti-FXa at Day 1 (0.5-1.5 Hours Postdose) | 66.93 ± 23.9 | 99.46 ± 60.6 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Anti-FXa at Day 1 (1.5-4 Hours Postdose) | 74.06 ± 32.4 | 104.57 ± 55.5 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Anti-FXa at Day 4 (6-8 Hours Postdose) | 74.21 ± 60.6 | — |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Anti-FXa at Month 3 (Up to 3 Hours Predose) | 60.51 ± 29.4 | 53.41 ± 15.0 |
TEAEs were defined as those adverse events (AEs) that occurred from the first day of study drug to the last day of study drug + 2 days inclusive. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
| percentage of participants | Rivaroxaban (Part A) | Rivaroxaban (Part B) | Aspirin (Part B) |
|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 91.7 | 85.9 | 85.3 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Anti-FXa at Month 3 (0.5-1.5 Hours Postdose) | — | 110.90 ± 75.8 |
Anti-FXa was assessed as pharmacodynamic parameter. Each participant was assessed once within the specified time-range and the average of the participants included in the given time-range is presented here.
| mcg/L | Rivaroxaban (Part A) | Rivaroxaban (Part B) |
|---|---|---|
| Anti-FXa at Month 3 (2.5-4 Hours Postdose) | — | 93.48 ± 50.3 |
Collected over Up to 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rivaroxaban (Part A) | 0/12 (0%) | 6/12 (50%) | 11/12 (91.7%) |
| Rivaroxaban (Part B) | 0/64 (0%) | 19/64 (29.7%) | 48/64 (75%) |
| Aspirin (Part B) | 0/34 (0%) | 8/34 (23.5%) | 26/34 (76.5%) |
| Event | Rivaroxaban (Part A) | Rivaroxaban (Part B) | Aspirin (Part B) |
|---|---|---|---|
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 2/12 | 9/64 | 2/34 |
| PyrexiaGeneral disorders | 1/12 | 0/64 | 0/34 |
| BronchitisInfections and infestations | 1/12 | 0/64 | 0/34 |
| LaryngitisInfections and infestations | 1/12 | 1/64 | 0/34 |
| PneumoniaInfections and infestations | 1/12 | 1/64 | 1/34 |
| Viral InfectionInfections and infestations | 1/12 | 0/64 | 0/34 |
| Swelling FaceGeneral disorders | 0/12 | 0/64 | 1/34 |
| InfluenzaInfections and infestations | 0/12 | 1/64 | 1/34 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 0/12 | 0/64 | 1/34 |
| Wound AbscessInfections and infestations | 0/12 | 0/64 | 1/34 |
| Event | Rivaroxaban (Part A) | Rivaroxaban (Part B) | Aspirin (Part B) |
|---|---|---|---|
| VomitingGastrointestinal disorders | 3/12 | 9/64 | 3/34 |
| PyrexiaGeneral disorders | 0/12 | 16/64 | 7/34 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 3/12 | 0/64 | 1/34 |
| NasopharyngitisInfections and infestations | 1/12 | 14/64 | 6/34 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/12 | 12/64 | 4/34 |
| DiarrhoeaGastrointestinal disorders | 2/12 | 3/64 | 2/34 |
| BronchitisInfections and infestations | 2/12 | 3/64 | 0/34 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/12 | 9/64 | 5/34 |
| Viral InfectionInfections and infestations | 2/12 | 2/64 | 1/34 |
| Dermatitis DiaperSkin and subcutaneous tissue disorders | 2/12 | 0/64 | 0/34 |
| Age, Continuous(years) | Rivaroxaban (Part A) | Rivaroxaban (Part B) | Aspirin (Part B) | Total |
|---|---|---|---|---|
| Mean | 2.5 ± 0.67 | 4.1 ± 1.74 | 4.2 ± 1.8 | 3.9 ± 1.74 |
| Sex: Female, Male(Participants) | Rivaroxaban (Part A) | Rivaroxaban (Part B) | Aspirin (Part B) | Total |
|---|---|---|---|---|
| Female | 5 | 30 | 11 | 46 |
| Male | 7 | 36 | 23 | 66 |
| Ethnicity (NIH/OMB)(Participants) | Rivaroxaban (Part A) | Rivaroxaban (Part B) | Aspirin (Part B) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 22 | 11 | 34 |
| Not Hispanic or Latino | 11 | 42 | 19 | 72 |
| Unknown or Not Reported | 0 | 2 | 4 | 6 |
| Race/Ethnicity, Customized(Participants) | Rivaroxaban (Part A) | Rivaroxaban (Part B) | Aspirin (Part B) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 14 | 7 | 21 |
| Black or African American | 3 | 8 | 1 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| White | 8 | 40 | 20 | 68 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 3 | 5 |
| Other | 1 | 2 | 3 | 6 |
| Region of Enrollment(Participants) | Rivaroxaban (Part A) | Rivaroxaban (Part B) | Aspirin (Part B) | Total |
|---|---|---|---|---|
| ARGENTINA | 0 | 5 | 1 | 6 |
| BELGIUM | 0 | 5 | 4 | 9 |
| BRAZIL | 0 | 7 | 10 | 17 |
| CANADA | 0 | 3 | 3 | 6 |
| JAPAN | 0 | 8 | 1 | 9 |
| MALAYSIA | 0 | 5 | 5 | 10 |
| MEXICO | 0 | 6 | 2 | 8 |
| NETHERLANDS | 0 | 1 | 0 | 1 |
| SPAIN | 5 | 1 | 0 | 6 |
| UNITED STATES | 7 | 25 | 8 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2016 to primary completion in Jul 2020, 44 months.
Results were first posted in Mar 2022, 1 year 8 months after primary completion. A results delay was requested in Jul 2021.
Of 27 phase 3 interventional studies under Thrombosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 57. This study's 44 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rivaroxaban · Aspirin
Janssen Research & Development, LLC →